|Bid||1.21 x 2200|
|Ask||1.24 x 2000|
|Day's Range||1.18 - 1.20|
|52 Week Range||1.04 - 1.85|
|PE Ratio (TTM)||-3.64|
|Earnings Date||Sep 11, 2017 - Sep 15, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||2.75|
Developed by the Israeli biotech Pluristem, the injection aims to help body tissue that’s been damaged by radiation.
Austria’ s regulatory health agency clears CLI study and joins the U.S., U.K., and Germany in conducting the 250- patient Phase III trial HAIFA, Israel, July 10, 2017-- Pluristem Therapeutics Inc., a leading ...
HAIFA, Israel, June 29, 2017-- Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, announced today that new data from its non-human primates pilot study evaluating ...